Table 2.
Patient characteristics and immunosuppressive medications taken.
| Patient 1* | Patient 2 | Patient 3 | Patient 4 | Patient 5 | |
|---|---|---|---|---|---|
| A) Patient characteristics | |||||
| Age, years | 29 | 46 | 26 | 64 | 22 |
| Gender | F | F | M | F | F |
| Ethnicity | Caucasian | Caucasian | African | Caucasian | Caucasian |
| ALT, IU/L | 200 | 24 | 16 | 15 | 19 |
| Creatinine, μM/L | 78 | 63 | 57 | 58 | 59 |
| IgG, g/L | 22 | 21 | 15 | 13.3 | 11.7 |
| ANA | 1:1,600 | Negative | 1:400 | 1:1,600 | 1:400 |
| LKM | Negative | Negative | Negative | Negative | Negative |
| F-Actin | Positive | Positive | Negative | Negative | Negative |
| SLA | Negative | Positive | Negative | Positive | Positive |
| SMA | Positive | 1:160 | 1:320 | 1:40 | 1:80 |
| UKELD | 50 | 46 | 45 | 44 | 43 |
| B) Immunosuppressive medications | |||||
| Budesonide | 6 mg | ||||
| Prednisolone | 15 mg | 7.5 mg | 20 mg | 10 mg | |
| Azathioprine | 50 mg | 100 mg | 75 mg | ||
| Tacrolimus | 4 mg | ||||
| Mycophenolate mofetil | 2 g | ||||
(A) Patients’ characteristics. Patient demographics and blood levels of ALT, creatinine, immunoglobulin G (IgG), auto-antibody profile including ANA, LKM, SLA, SMA and UKELD scores. Patient 1* underwent leukapheresis and GMP-Treg isolation but did not receive cells due to poor labelling. (B) Immunosuppressive medications taken by the patients. Total daily doses are shown. ALT, alanine aminotransferase; ANA, anti-nuclear antibody; LKM, anti-liver, kidney, microsomal antibody; SLA, soluble liver antigen antibody; SMA, anti-smooth muscle antibody; Treg, regulatory T cell; UKELD, United Kingdom end-stage liver disease.